Results for tag: "Peroxisome Proliferator Activated Receptor"

The Peroxisome Proliferator Activated Receptor (PPAR) market is a subset of the Endocrine and Metabolic Disorders Drugs market. PPARs are a family of nuclear receptors that regulate gene expression and are involved in lipid and glucose metabolism. PPAR agonists are used to treat type 2 diabetes, dyslipidemia, and other metabolic disorders. They are also being studied for their potential to treat obesity, non-alcoholic fatty liver disease, and other metabolic diseases. PPAR agonists are available in both oral and injectable forms. The most commonly prescribed PPAR agonists are pioglitazone, rosiglitazone, and glitazarsen. These drugs are used to improve glycemic control and reduce the risk of cardiovascular events in patients with type 2 diabetes. The PPAR market is highly competitive, with several major pharmaceutical companies developing and marketing PPAR agonists. These include Merck, Novo Nordisk, Sanofi, and Takeda. Other companies, such as Eli Lilly, Boehringer Ingelheim, and AstraZeneca, are also involved in the development of PPAR agonists. Show Less Read more